InvestorsHub Logo
Followers 33
Posts 2843
Boards Moderated 2
Alias Born 10/24/2015

Re: None

Monday, 06/01/2020 1:15:21 PM

Monday, June 01, 2020 1:15:21 PM

Post# of 79
AUTO3 is a first-in-class anti-CD19/22 CAR-T with novel signaling domains (OX40 & 41BB), design and manufacturing process. An outpatient cohort has been initiated with potential to move to a pivotal trial early next year.

Here is a link to the conference call and slides https://edge.media-server.com/mmc/p/j5jihpte https://autolus.gcs-web.com/static-files/de412b07-3021-4200-a187-f820cad01416
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AUTL News